- Granting of patent number AU2019204496 strengthens Anatara's intellectual property position (IP) in the treatment and prevention of diarrhea caused by pathogenic microbes
- The patent provides the pathway for Anatara to further pursue commercialisation opportunities for Detach(R)
- Patent expires on
- Piglet challenge study commenced
Anatara's animal heath product, Detach(R), uses the patent as a non-antibiotic approach to aid in the control of diarrheal disease (known as scour), developed using bromelain, an extract from pineapple stems.
The patent claims cover an oral formulation of bromelain effective to treat and prevent diarrhea caused by pathogenic microbes. This formulation does not kill pathogenic microbes, and thus does not facilitate the proliferation of anti-microbial resistant organisms. The patent is fully owned by Anatara and will expire on
The Company remains encouraged by the progress in animal health areas, particularly the opportunity to extend into feed products targeting the need for products for growth enhancement without antibiotics or zinc oxide.
Commenting on the patent grant, Anatara Chief Executive Officer
Piglet challenge study commenced
The BONIFF-SMEC piglet challenge study for enterotoxigenic Escherichia Coli, anticipated to be completed in
The BONIFF-SMEC study is being done in partnership with
Pleasingly, as announced on the
"Having focused our efforts on research and development over a number of years, we have developed a strong animal health pipeline and I look forward to providing the market with an update on the commercial significance of both the pig and poultry challenge trials in the coming months", added Mr Lydeamore.
About
Contact:
Investor and Media inquiries
Steven Lydeamore
Chief Executive Officer
T: +61-438-027-172
E: slydeamore@anatara.com
Chair
T: +61-437-211-200
E: smacleman@anatara.com
Copyright (C) 2021 ABN Newswire. All rights reserved., source